Literature DB >> 1018890

Observations on the transmission, immunology, clinical signs and chemotherapy of dourine (Trypanosoma equiperdum infection) in horses, with special reference to cerebro-spinal fluid.

P R Barrowman.   

Abstract

This paper is a record of observations on the transmission and clinical signs of dourine in naturally infected cases of known duration, and of temporal and quantitative aspects of the immune response in blood and cerebro-spinal fluid. Included in the record are observations on the presence of Trypanosoma equiperdum parasites in these body fluids and methods for their detection. There is evidence that the occurrence of nervous symptoms and lesions in infected horses is associated with the presence of Trypanosoma equiperdum parasites in cerebro-spinal fluid. The suitability of cerebro-spinal fluid as an environment for the parasite and its relationship with nervous manifestations of the disease are discussed. Observations support the previously reported lesions of peripheral polyneuritis and suggest a possible correltation between the consitstent position of the nervous lesions and the drainage of cerebro-spinal fluid containing the parasite. Chemotherapy with an experimental drug MSbE was used with varying results in 4 horses at different stages of infection.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1018890

Source DB:  PubMed          Journal:  Onderstepoort J Vet Res        ISSN: 0030-2465            Impact factor:   1.792


  2 in total

1.  Comparative diagnosis of parasitological, serological, and molecular tests in dourine-suspected horses.

Authors:  Fikru Regassa Gari; Hagos Ashenafi; Alemu Tola; Bruno M Goddeeris; Filip Claes
Journal:  Trop Anim Health Prod       Date:  2010-06-06       Impact factor: 1.559

2.  A proline racemase based PCR for identification of Trypanosoma vivax in cattle blood.

Authors:  Regassa Fikru; Ashenafi Hagos; Stijn Rogé; Armando Reyna-Bello; Mary Isabel Gonzatti; Bekana Merga; Bruno Maria Goddeeris; Philippe Büscher
Journal:  PLoS One       Date:  2014-01-08       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.